Literature DB >> 24652111

Hepatotoxicity of anti-TNF agents.

Maurizio Bonacini1, Marwan Ghabril, Herbert L Bonkovsky.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24652111     DOI： 10.1007/s10620-014-3109-3

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN： 0163-2116            Impact factor:   3.199


× No keyword cloud information.
  8 in total

1.  Infliximab-induced autoimmune hepatitis in Crohn's disease treated with budesonide and mycophenolate.

Authors:  K Subramaniam; S Chitturi; M Brown; P Pavli
Journal:  Inflamm Bowel Dis       Date:  2011-08-30       Impact factor: 5.325

2.  Autoimmune hepatitis in two psoriasis patients treated with inflixmab.

Authors:  Catherine Goujon; Karima Dahel; Frédéric Bérard; Isabelle Guillot; Nathalie Gunera-Saad; Jean-François Nicolas
Journal:  J Am Acad Dermatol       Date:  2010-08       Impact factor: 11.527

3.  Autoimmune hepatitis associated with infliximab in a patient with psoriatic arthritis.

Authors:  V Germano; A Picchianti Diamanti; G Baccano; E Natale; A Onetti Muda; R Priori; G Valesini
Journal:  Ann Rheum Dis       Date:  2005-10       Impact factor: 19.103

4.  Drug induced liver injury and its relationship to autoimmune hepatitis.

Authors:  Christina Weiler-Normann; Christoph Schramm
Journal:  J Hepatol       Date:  2011-03-09       Impact factor: 25.083

Review 5.  Infliximab-related hepatitis: a case study and literature review.

Authors:  Francisco Colina; Aída Molero; Begoña Casís; Pilar Martínez-Montiel
Journal:  Dig Dis Sci       Date:  2013-05-05       Impact factor: 3.199

Review 6.  Liver injury from tumor necrosis factor-α antagonists: analysis of thirty-four cases.

Authors:  Marwan Ghabril; Herbert L Bonkovsky; Clarissa Kum; Tim Davern; Paul H Hayashi; David E Kleiner; Jose Serrano; Jim Rochon; Robert J Fontana; Maurizio Bonacini
Journal:  Clin Gastroenterol Hepatol       Date:  2013-01-17       Impact factor: 11.382

7.  Clinically significant liver injury in patients treated with natalizumab.

Authors:  S Bezabeh; C M Flowers; C Kortepeter; M Avigan
Journal:  Aliment Pharmacol Ther       Date:  2010-02-16       Impact factor: 8.171

8.  Serious liver disease induced by infliximab.

Authors:  Gabriel J Tobon; Carlos Cañas; Juan-Jose Jaller; Juan-Carlos Restrepo; Juan-Manuel Anaya
Journal:  Clin Rheumatol       Date:  2006-03-18       Impact factor: 3.650
  8 in total
  4 in total

Review 1.  Hepatotoxicity Associated with the Use of Anti-TNF-α Agents.

Authors:  Joshua B French; Maurizio Bonacini; Marwan Ghabril; David Foureau; Herbert L Bonkovsky
Journal:  Drug Saf       Date:  2016-03       Impact factor: 5.606

Review 2.  Remicade® (infliximab): 20 years of contributions to science and medicine.

Authors:  Richard Melsheimer; Anja Geldhof; Isabel Apaolaza; Thomas Schaible
Journal:  Biologics       Date:  2019-07-30

Review 3.  Hepatic complications induced by immunosuppressants and biologics in inflammatory bowel disease.

Authors:  My-Linh Tran-Minh; Paula Sousa; Marianne Maillet; Matthieu Allez; Jean-Marc Gornet
Journal:  World J Hepatol       Date:  2017-05-08

Review 4.  Interactions between Myc and Mediators of Inflammation in Chronic Liver Diseases.

Authors:  Ting Liu; Yu Zhou; Kwang Suk Ko; Heping Yang
Journal:  Mediators Inflamm       Date:  2015-10-05       Impact factor: 4.711
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.